(R)-Equol

CAS No. 221054-79-1

(R)-Equol( (+)-Equol )

Catalog No. M26529 CAS No. 221054-79-1

(R)-Equol is an ERα and ERβ agonist with Kis of 27.4 and 15.4 nM, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 32 In Stock
5MG 51 In Stock
10MG 87 In Stock
25MG 146 In Stock
50MG 214 In Stock
100MG 322 In Stock
200MG 475 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    (R)-Equol
  • Note
    Research use only, not for human use.
  • Brief Description
    (R)-Equol is an ERα and ERβ agonist with Kis of 27.4 and 15.4 nM, respectively.
  • Description
    (R)-Equol is an ERα and ERβ agonist with Kis of 27.4 and 15.4 nM, respectively.(In Vitro):(R)-Equol produced a dose-dependent inhibitory effect on the invasive ability of MDA-MB-231 cells, and this inhibitory effect was obvious at the highest test concentration (50 μM).Following 48-h exposure to (R)-Equol, invasion is reduced by 62% (p=0.009, versus untreated cells) with 50 μM (R)-Equol. Matrix metalloproteinase-2 (MMP-2) expression is significantly down-regulated following treatment with 50 μM (R)-Equol (p=0.035) .(In Vivo):In Animals, (R)-Equol has a significantly reduced number of palpable tumors over time when compared with Controls (P=0.002).In addition, the number of palpable tumors formed by each rat in the (R)-Equol fed group was significantly lower than that of rats treated with S-(-)equol (P = 0.008). (R)-Equol-fed animals have 43% fewer tumors than the control group and this difference is highly statistically significant (P=0.004). The number of tumors/tumor-bearing animals is significantly lower in the animals fed (R)-Equol compare with Controls (3.3±0.4 versus 5.5±0.5, P=0.004). At necropsy, the mean (±SEM) tumor weight per animal for (R)-Equol fed rats (5.3±1.1 mg) is significantly reduced (P=0.04) when compared with Controls (9.9±1.4 mg). Feeding the (R)-Equol diet results in significantly increased tumor latency (P=0.003) .
  • In Vitro
    (R)-Equol is an agonist of both ERα and ERβ with Kis of 27.4 and 15.4 nM, respectively. (R)-Equol induces a dose-dependent inhibitory effect on the invasive capacity of MDA-MB-231 cells that is significant at the highest concentration tested (50 μM). Following 48-h exposure to (R)-Equol, invasion is reduced by 62% (p=0.009, versus untreated cells) with 50 μM (R)-Equol. Matrix metalloproteinase-2 (MMP-2) expression is significantly down-regulated following treatment with 50 μM (R)-Equol (p=0.035).
  • In Vivo
    Animals fed (R)-Equol have a significantly reduced number of palpable tumors over time when compare with Controls (P=0.002). Furthermore, the number of palpable tumors formed per rat in the (R)-Equol-fed group is significantly lower than that of rats treated with S-(-)equol (P=0.008).(R)-Equol-fed animals have 43% fewer tumors than the control group and this difference is highly statistically significant (P=0.004). The number of tumors/tumor-bearing animal is significantly lower in the animals fed (R)-Equol compare with Controls (3.3±0.4 versus 5.5±0.5, P=0.004). At necropsy, the mean (±SEM) tumor weight per animal for (R)-Equol fed rats (5.3±1.1 mg) is significantly reduced (P=0.04) when compare with Controls (9.9±1.4 mg). Feeding the (R)-Equol diet results in significantly increased tumor latency (P=0.003).
  • Synonyms
    (+)-Equol
  • Pathway
    Endocrinology/Hormones
  • Target
    Estrogen Receptor/ERR
  • Recptor
    mPGES-1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    221054-79-1
  • Formula Weight
    242.274
  • Molecular Formula
    C15H14O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (412.76 mM)
  • SMILES
    Oc1ccc(cc1)[C@@H]1COc2cc(O)ccc2C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Guerrero, M.D., Aquino, M., Bruno, I., et al. Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the γ-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prostaglandin E synthase-1 expression. Journal of Medicinal Chemistry 50, 2176-2184 (2007).
molnova catalog
related products
  • Endoxifen

    A metabolite of tamoxifen, orally active non-steroidal selective estrogen receptor modulator (SERM) for the treatment of estrogen receptor-positive breast cancer.

  • 5Beta-Pregnane-3Alph...

    An inactive metabolite of progesterone by reduction at C5, C3, and C20 position.

  • Ulipristal acetate

    Ulipristal acetate(CDB2914) is a novel selective progesterone receptor modulator (SPRM) for the treatment of benign gynecological conditions such as uterine myoma.